20.40

4.88% 0.95

After Hours: 20.40

Anaptysbio Inc (ANAB)

Overview News Price History Option Chain Financials Discussions Forecast

Anaptysbio Inc stock is traded at $20.40, with a volume of 363.93K. It is up +4.88% in the last 24 hours and up +12.71% over the past month. AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Previous Close:

$19.45

Open:

$19.54

24h Volume:

363.93K

Relative Volume:

0.38

Market Cap:

$575.27M

Revenue:

$17.16M

Net Income/Loss:

$-163.62M

P/E Ratio:

-3.3553

EPS:

-6.08

Net Cash Flow:

$-121.61M

1W Performance:

+4.19%

1M Performance:

+12.71%

6M Performance:

+7.37%

1Y Performance:

-20.31%

1-Day Range:

$19.21

$20.79

1-Week Range:

$19.09

$21.14

52-Week Range:

$12.21

$41.31

Anaptysbio Inc Stock (ANAB) Company Profile

Name

Anaptysbio Inc

Sector

Healthcare (1147)

Industry

Biotechnology (673)

Phone

858-362-6295

Address

10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA

Employee

136

Twitter

@anaptysbio

Next Earnings Date

2024-11-08

Latest SEC Filings

ANAB's Discussions on Twitter

Compare ANAB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ANAB Anaptysbio Inc	20.40	575.27M	17.16M	-163.62M	-121.61M	-6.08
VRTX Vertex Pharmaceuticals Inc	434.38	110.32B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	584.99	59.13B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	561.75	34.75B	2.58B	1.06B	-1.28B	16.33
ALNY Alnylam Pharmaceuticals Inc	283.40	33.69B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	225.77	25.49B	3.81B	-644.79M	-669.77M	-6.24

Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-04-25	Initiated	Wolfe Research	Outperform
Dec-11-24	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-02-24	Downgrade	BTIG Research	Buy → Neutral
Jul-22-24	Initiated	H.C. Wainwright	Buy
Jul-19-24	Upgrade	JP Morgan	Neutral → Overweight
Apr-16-24	Initiated	Leerink Partners	Outperform
Apr-11-24	Initiated	Wells Fargo	Overweight
Mar-12-24	Upgrade	Wedbush	Neutral → Outperform
Feb-26-24	Initiated	BTIG Research	Buy
Feb-21-24	Initiated	Stifel	Buy
Feb-16-24	Initiated	Piper Sandler	Overweight
May-22-23	Upgrade	JP Morgan	Underweight → Neutral
May-18-23	Initiated	TD Cowen	Outperform
Jan-06-23	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-01-22	Upgrade	Guggenheim	Neutral → Buy
Sep-19-22	Resumed	H.C. Wainwright	Buy
Sep-13-22	Downgrade	Truist	Buy → Hold
Sep-01-22	Initiated	Raymond James	Outperform
Mar-22-22	Downgrade	Guggenheim	Buy → Neutral
Jun-22-21	Initiated	H.C. Wainwright	Buy
May-21-21	Initiated	UBS	Neutral
Mar-16-21	Upgrade	Truist	Hold → Buy
Mar-09-21	Downgrade	Wedbush	Outperform → Neutral
Mar-08-21	Downgrade	JP Morgan	Overweight → Underweight
Feb-11-21	Upgrade	JP Morgan	Underweight → Overweight
Oct-27-20	Upgrade	Wedbush	Neutral → Outperform
Oct-14-20	Upgrade	Guggenheim	Neutral → Buy
Nov-08-19	Downgrade	JP Morgan	Overweight → Underweight
Nov-08-19	Downgrade	Jefferies	Buy → Hold
Nov-08-19	Downgrade	SunTrust	Buy → Hold
Nov-08-19	Downgrade	Wedbush	Outperform → Neutral
Jun-21-19	Downgrade	Credit Suisse	Outperform → Neutral
Jun-21-19	Downgrade	Stifel	Buy → Hold
Dec-20-18	Initiated	H.C. Wainwright	Buy
Nov-21-18	Initiated	JP Morgan	Overweight
Jul-19-18	Initiated	Credit Suisse	Outperform
Apr-04-18	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Mar-27-18	Reiterated	Stifel	Buy
Mar-06-18	Reiterated	Stifel	Buy
Feb-15-18	Reiterated	SunTrust	Buy
Jan-23-18	Reiterated	Credit Suisse	Outperform
Nov-15-17	Initiated	SunTrust	Buy
Nov-09-17	Initiated	Jefferies	Buy
Oct-11-17	Reiterated	RBC Capital Mkts	Outperform
Sep-15-17	Initiated	RBC Capital Mkts	Outperform

View All

Anaptysbio Inc Stock (ANAB) Latest News

12:08 PM

AnaptysBio Reports Strong Q1 2025 Results and Progress - TipRanks

12:08 PM

May 15, 2025

AnaptysBio, Inc. (NASDAQ:ANAB) Shares Bought by Tower Research Capital LLC TRC - Defense World

May 15, 2025

Wells Fargo & Company MN Cuts Stake in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat

May 15, 2025

May 14, 2025

AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

May 14, 2025

Bridgefront Capital LLC Acquires New Holdings in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat

May 14, 2025

Fairmount Funds Management LLC Makes New Investment in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat

May 14, 2025

May 13, 2025

Q2 EPS Estimates for AnaptysBio Raised by Leerink Partnrs - MarketBeat

May 13, 2025

Granahan Investment Management LLC Buys New Shares in AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat

May 13, 2025

HC Wainwright Has Pessimistic View of AnaptysBio Q2 Earnings - MarketBeat

May 13, 2025

May 12, 2025